Prelude Therapeutics Inc (PRLD)
$6.56
$-0.03
(-0.46%)
As on 26-Aug-2026 16:00EDT
Market cap
$529 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
3.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
65,075,350
6 Years Aggregate
CFO
$-359.12 Mln
EBITDA
$-466.92 Mln
Net Profit
$-439.13 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Prelude Therapeutics Inc (PRLD)
| 126.2 | 71.3 | 53.6 | 416.5 | 20.3 | -28.3 | -- |
|
BSE Sensex*
| -8.9 | 1.4 | 1.5 | -4.5 | 5.9 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Prelude Therapeutics Inc (PRLD)
| 127.5 | -69.8 | -29.3 | -51.5 | -82.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Prelude Therapeutics Inc (PRLD)
|
6.6 | 529.1 | 22.4 | -60.5 | -269.7 | -59.8 | -- | 3.9 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 359.8 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the... treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Read more
-
Founder, CEO & Director
Dr. Krishna Vaddi D.V.M., Ph.D.
-
Founder, CEO & Director
Dr. Krishna Vaddi D.V.M., Ph.D.
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Prelude Therapeutics Inc (PRLD)
What is the current share price of Prelude Therapeutics Inc (PRLD) Today?
The share price of Prelude Therapeutics Inc (PRLD) is $6.56 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Prelude Therapeutics Inc (PRLD) has given a return of 20.28% in the last 3 years.
What is the current PB & PE ratio of Prelude Therapeutics Inc (PRLD)?
Since, TTM earnings of Prelude Therapeutics Inc (PRLD) is negative, P/E ratio is not available.
The P/B ratio of Prelude Therapeutics Inc (PRLD) is 3.87 times as on 21-Aug-2026, a 28 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.83 |
2.66 |
2024 |
-0.76 |
0.74 |
2023 |
-2.44 |
1.25 |
2022 |
-2.70 |
1.48 |
2021 |
-5.21 |
2.02 |
What is the 52 Week High and Low of Prelude Therapeutics Inc (PRLD)?
The 52-week high and low of Prelude Therapeutics Inc (PRLD) are Rs 6.83 and Rs 0.98 as of 27-Aug-2026.
What is the market cap of Prelude Therapeutics Inc (PRLD)?
Prelude Therapeutics Inc (PRLD) has a market capitalisation of $ 529 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Prelude Therapeutics Inc (PRLD)?
Before investing in Prelude Therapeutics Inc (PRLD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.